All updates
All updates
today 33文献与产业新闻评分5454 文献与产业新闻评分4747 STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map
文献与产业新闻评分4747 Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
文献与产业新闻评分1212 Baylor Genetics hit by cybersecurity attack targeting patient, staff information
文献与产业新闻评分1919 STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
中文产业新闻Chinese source评分6666 从追赶到并跑：22亿美元授权写尽中国双抗ADC新位置
文献与产业新闻精选评分6161 Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators
文献与产业新闻评分3030 Protuoso Bio: Building mix-and-match multi-functional biologics
文献与产业新闻评分4747 Boulevard: Homing in on B cell biology in autoimmunity
文献与产业新闻评分3636 STAT+: Up and down the ladder: The latest comings and goings
文献与产业新闻评分4242 Syndicate backs MapLight, illuminating path forward in schizophrenia: Public Equity Report
中文产业新闻Chinese source评分6060 赛默飞10.75亿美元剥离微生物业务，前铂金埃尔默CEO执掌新公司
文献与产业新闻评分4141 STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
文献与产业新闻评分4545 Skye and Redx form new entity with $125M to advance fibrosis assets
文献与产业新闻评分4848 It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
文献与产业新闻评分3838 ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
文献与产业新闻评分3939 MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
文献与产业新闻评分5353 STAT+: Commure terminates payments under its customer referral programs tied to AI products
文献与产业新闻评分4040 Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
文献与产业新闻评分4444 Khartis emerges from stealth with $95M to challenge Tepezza: Venture Report
文献与产业新闻评分3333 Vir CFO O’Byrne joining Olema
中文产业新闻精选Chinese source评分7777 核药赛道最大并购，Curium与Lantheus合并协议总对价最高80亿美元
文献与产业新闻评分5151 It's crunch time for Karyopharm as company faces potential default next month
文献与产业新闻评分3434 STAT+: Eli Lilly targets booming black market for retatrutide
文献与产业新闻评分3636 Chutes & Ladders—Former Legend CEO lands at K2
文献与产业新闻精选评分6363 PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
文献与产业新闻评分4545 Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
文献与产业新闻评分2929 Abbott to pump up blood supply with $1M college sports prize amid US crisis
文献与产业新闻评分3737 Medtronic veteran Bill Shields crosses over to become CEO at valve disease startup
中文产业新闻Chinese source评分6363 Jazz Pharmaceuticals以最高13.2亿美元收购罕见病Biotech Actio Biosciences
中文产业新闻精选Chinese source评分7171 翰森NewCo Avere再获5亿美元私募融资，口服IL-23环肽AVR-001累计融资达8.2亿美元
中文产业新闻Chinese source评分6767 甘李药业授予Menarini博凡格鲁肽肥胖适应症独家许可，首付款6200万欧元
中文产业新闻Chinese source评分6767 甘李药业与美纳里尼就博凡格鲁肽注射液签署7.26亿欧元欧洲独家许可
中文产业新闻精选Chinese source评分6969 甘李药业与Menarini就GLP-1双周制剂博凡格鲁肽签署欧洲独家许可协议
中文产业新闻精选Chinese source评分7373 艾伯维登记 ABBV-1480 三期 NSCLC 试验，头对头帕博利珠单抗联合化疗
中文产业新闻Chinese source评分6565 恒瑞NewCo Braveheart Bio登陆纳斯达克 扩大IPO募资3.825亿美元
中文产业新闻Chinese source评分6060 艾佩迪生物完成1.15亿美元B轮融资，开发DPP1抑制剂
中文产业新闻精选Chinese source评分7878 Curium拟以最高80亿美元私有化Lantheus，为核药发展史上最大并购
中文产业新闻Chinese source评分6262 KKR以约57亿美元收购医疗器械CDMO Integer Holdings并将其私有化